netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
01.02  Expand sub section  Antispasmodics and other drugs altering gut motility
01.02  Expand sub section  Antimuscarinics
Hyoscine Butylbromide (Buscopan®)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice Tablets
Injection 
01.02  Expand sub section  Other antispasmodics
Mebeverine Hydrochloride
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice Tablets
Oral suspension 
Alverine Citrate (Spasmonal®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
Peppermint Oil e/c capsules
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary  
   
01.02  Expand sub section  Motility stimulants
Metoclopramide
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice Tablets
Oral solution
Injection

note Should only be prescribed for short-term use (up to 5 days). For adults, the maximum dose in 24 hours is 30mg. 
Domperidone
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets
Suspension

unlicensedunlicensed indication

note Studies have shown that domperidone may be associated with a small increased risk of serious cardiac side effects.
DotThese risks may be higher in patients older than 60 years and in patients who receive daily oral doses of more than 30 mg.
DotDomperidone should be used at the lowest effective dose for the shortest possible time
DotMaximum treatment duration should not exceed one week
DotDomperidone is contra-indicated in patients who are taking concomitant medication known to cause QT prolongation (such as ketoconazole and erythromycin) 
Link  MHRA:Domperidone: risks of cardiac side effects
   
Erythromycin
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary Tablets
Oral Suspension
Intravenous infusion

unlicensedunlicensed indication 
Link  UKMi Q&A: What is the optimal prokinetic dose of erythromycin in adults
   
 ....
 Non Formulary Items
Acidex

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Atropine

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
 
Dicycloverine

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Black

Tablets
Syrup

 
Gastrocote

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
 
Ispaghula Husk with Mebeverine Hydrochloride  (Fybogel® Mebeverine)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
 
Lubiprostone  (Amitiza®)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Green 3
 
Peppermint water

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Peptac

View adult BNF View SPC online View childrens BNF
Non Formulary
 
Propantheline

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Drugs designated amber are suitable for shared care arrangements under a shared care protocol. Prescribing may be transferred from secondary to primary care once the patient is stabilised and agreed shared care arrangements have been established. Alternatively primary care may initiate under the supervision of secondary care if this option is given in the shared care document. It is recommended that shared care arrangements should be drawn up following local discussion and agreement by prescribing parties.   

Black

These products have been reviewed by the GM Joint Formulary Group and have been deemed not suitable for prescribing for adults in primary or secondary care within Greater Manchester. These decisions have been made on the basis of safety, efficacy and cost-effectiveness of the products.  

Green

Not used   

Green 1

Drugs designated green1 are suitable for initiation and ongoing prescribing within primary care.   

Green 2

Drugs designated green2 can be initiated by primary care following written or verbal advice from a specialist and then be subsequently safely prescribed in primary care with little or no monitoring required.  

Green 3

Drugs designated green3 are suitable for on-going prescribing within primary care after specialist initiation and an initial review (unless specified) in secondary care. Little or no monitoring is required.  

Grey

Not suitable for routine prescribing but may be suitable for a defined patient population. Whilst prescribers should think very carefully before prescribing or recommending any of the products on the grey list, there may be exceptional instances when the use of one of these products is necessary for a particular patient.   

Red

Drugs designated red are considered to be specialist medicines and prescribing responsibility for these medicines should normally remain with the consultant or specialist clinician. These drugs should not be initiated or prescribed in primary care. It is recommended that the supply of these specialist medicines should be organised via the hospital pharmacy, this may include arranging for supply via a home care company.   

netFormulary